IS7749A - Pýrimídínafleiður og notkun þeirra sem CB2 beina - Google Patents

Pýrimídínafleiður og notkun þeirra sem CB2 beina

Info

Publication number
IS7749A
IS7749A IS7749A IS7749A IS7749A IS 7749 A IS7749 A IS 7749A IS 7749 A IS7749 A IS 7749A IS 7749 A IS7749 A IS 7749A IS 7749 A IS7749 A IS 7749A
Authority
IS
Iceland
Prior art keywords
direct
pyrimidine derivatives
pyrimidine
derivatives
Prior art date
Application number
IS7749A
Other languages
English (en)
Inventor
John Eatherton Andrew
Martin Paul Giblin Gerard
Howard Green Richard (l βtinn)
Original Assignee
Glaxo Group Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=31948030&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IS7749(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GB0219501A external-priority patent/GB0219501D0/en
Priority claimed from GB0309326A external-priority patent/GB0309326D0/en
Application filed by Glaxo Group Limited filed Critical Glaxo Group Limited
Publication of IS7749A publication Critical patent/IS7749A/is

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/42—One nitrogen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
IS7749A 2002-08-21 2005-03-17 Pýrimídínafleiður og notkun þeirra sem CB2 beina IS7749A (is)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0219501A GB0219501D0 (en) 2002-08-21 2002-08-21 Compounds
GB0309326A GB0309326D0 (en) 2003-04-24 2003-04-24 Compounds
PCT/EP2003/009217 WO2004018433A1 (en) 2002-08-21 2003-08-19 Pyrimidine derivatives and their use as cb2 modulators

Publications (1)

Publication Number Publication Date
IS7749A true IS7749A (is) 2005-03-17

Family

ID=31948030

Family Applications (1)

Application Number Title Priority Date Filing Date
IS7749A IS7749A (is) 2002-08-21 2005-03-17 Pýrimídínafleiður og notkun þeirra sem CB2 beina

Country Status (34)

Country Link
US (2) US7635701B2 (is)
EP (2) EP1878725B1 (is)
JP (1) JP4583174B2 (is)
KR (1) KR20050058367A (is)
CN (1) CN100351239C (is)
AP (1) AP2005003219A0 (is)
AR (1) AR041016A1 (is)
AT (2) ATE489369T1 (is)
AU (1) AU2003264076B2 (is)
BR (1) BR0313676A (is)
CA (1) CA2495880C (is)
CY (1) CY1107871T1 (is)
DE (2) DE60317348T2 (is)
DK (1) DK1539712T3 (is)
EA (2) EA012703B1 (is)
EC (1) ECSP055613A (is)
ES (1) ES2295682T3 (is)
IL (2) IL166552A0 (is)
IS (1) IS7749A (is)
MA (1) MA27428A1 (is)
MX (1) MXPA05001960A (is)
MY (1) MY137053A (is)
NO (1) NO20051451L (is)
NZ (1) NZ537886A (is)
OA (1) OA12910A (is)
PE (1) PE20040898A1 (is)
PL (1) PL376047A1 (is)
PT (1) PT1539712E (is)
SI (1) SI1539712T1 (is)
TW (1) TW200410946A (is)
UA (1) UA83194C2 (is)
UY (1) UY27939A1 (is)
WO (1) WO2004018433A1 (is)
ZA (1) ZA200500913B (is)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UY27939A1 (es) 2002-08-21 2004-03-31 Glaxo Group Ltd Compuestos
JP2006510597A (ja) 2002-09-27 2006-03-30 メルク　エンド　カムパニー　インコーポレーテッド 置換ピリミジン類
TW200505902A (en) 2003-03-20 2005-02-16 Schering Corp Cannabinoid receptor ligands
US20040259887A1 (en) * 2003-06-18 2004-12-23 Pfizer Inc Cannabinoid receptor ligands and uses thereof
GB0402355D0 (en) * 2004-02-03 2004-03-10 Glaxo Group Ltd Novel compounds
GB0402356D0 (en) * 2004-02-03 2004-03-10 Glaxo Group Ltd Novel compounds
KR20070011458A (ko) 2004-04-08 2007-01-24 탈자진 인코포레이티드 키나제의 벤조트리아진 억제제
EP1799656A4 (en) 2004-08-25 2009-09-02 Targegen Inc HETEROCYCLIC COMPOUNDS AND METHODS OF USE
GB0517188D0 (en) * 2005-08-22 2005-09-28 Glaxo Group Ltd Compounds
US8604042B2 (en) 2005-11-01 2013-12-10 Targegen, Inc. Bi-aryl meta-pyrimidine inhibitors of kinases
WO2007053452A1 (en) 2005-11-01 2007-05-10 Targegen, Inc. Bi-aryl meta-pyrimidine inhibitors of kinases
US8133900B2 (en) 2005-11-01 2012-03-13 Targegen, Inc. Use of bi-aryl meta-pyrimidine inhibitors of kinases
WO2007070760A2 (en) * 2005-12-15 2007-06-21 Boehringer Ingelheim International Gmbh Compounds which modulate the cb2 receptor
CA2643863A1 (en) * 2006-04-07 2007-10-18 Boehringer Ingelheim International Gmbh Compounds which modulate the cb2 receptor
WO2008014199A2 (en) 2006-07-28 2008-01-31 Boehringer Ingelheim International Gmbh Sulfonyl compounds which modulate the cb2 receptor
WO2008032764A1 (fr) * 2006-09-13 2008-03-20 Kyowa Hakko Kirin Co., Ltd. Dérivé hétérocyclique fusionné
EA200900403A1 (ru) 2006-09-25 2009-10-30 Бёрингер Ингельхайм Интернациональ Гмбх Соединения, которые модулируют рецептор св2
CA2664621A1 (en) * 2006-10-04 2008-04-10 F. Hoffmann-La Roche Ag Pyrazine-2-carboxamide derivatives
WO2008048914A1 (en) * 2006-10-17 2008-04-24 Boehringer Ingelheim International Gmbh Polycyclic compounds which modulate the cb2 receptor
CA2695613A1 (en) 2006-12-19 2008-06-26 Pharmos Corporation Sulfonamide derivatives with therapeutic indications
GB0705803D0 (en) * 2007-03-28 2007-05-02 Glaxo Group Ltd Novel compounds
AU2008323877A1 (en) * 2007-11-06 2009-05-14 Emory University Methods of identifying safe NMDA receptor antagonists
WO2009061652A1 (en) 2007-11-07 2009-05-14 Boehringer Ingelheim International Gmbh Compounds which modulate the cb2 receptor
EP2326629B1 (en) 2008-07-10 2013-10-02 Boehringer Ingelheim International GmbH Sulfone compounds which modulate the cb2 receptor
KR20110063485A (ko) 2008-09-25 2011-06-10 베링거 인겔하임 인터내셔날 게엠베하 Ｃｂ2 수용체를 선택적으로 조절하는 설포닐 화합물
TW201031649A (en) 2008-12-02 2010-09-01 Organon Nv 1-(4-(pyridin-2-yl)benzyl)imidazolidine-2,4-dione derivatives
TW201031650A (en) 2008-12-02 2010-09-01 Organon Nv 1-(biphenyl-4-ylmethyl)imidazolidine-2,4-dione
MX2011010396A (es) 2009-03-30 2011-10-24 Astellas Pharma Inc Compuesto de pirimidina.
US8299103B2 (en) 2009-06-15 2012-10-30 Boehringer Ingelheim International Gmbh Compounds which selectively modulate the CB2 receptor
EP2443107B1 (en) 2009-06-16 2018-08-08 Boehringer Ingelheim International GmbH Azetidine 2 -carboxamide derivatives which modulate the cb2 receptor
WO2011037795A1 (en) 2009-09-22 2011-03-31 Boehringer Ingelheim International Gmbh Compounds which selectively modulate the cb2 receptor
JP2013517271A (ja) 2010-01-15 2013-05-16 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｃｂ２受容体を調節する化合物
EP2542539B1 (en) 2010-03-05 2014-02-26 Boehringer Ingelheim International GmbH Tetrazole compounds which selectively modulate the cb2 receptor
WO2012012307A1 (en) 2010-07-22 2012-01-26 Boehringer Ingelheim International Gmbh Sulfonyl compounds which modulate the cb2 rece
PL2599774T3 (pl) * 2010-07-29 2017-01-31 Astellas Pharma Inc. Skondensowane związki pirydynowe, jako ligandy receptorów kannabinoidowych cb2
WO2012060847A1 (en) 2010-11-07 2012-05-10 Targegen, Inc. Compositions and methods for treating myelofibrosis
WO2014143661A1 (en) * 2013-03-15 2014-09-18 Waterfi, Llc Method for water-proofing elecronic components
EP2803668A1 (en) 2013-05-17 2014-11-19 Boehringer Ingelheim International Gmbh Novel (cyano-dimethyl-methyl)-isoxazoles and -[1,3,4]thiadiazoles
CN106414456B (zh) * 2013-10-23 2018-12-14 中央研究院 用于预防和治疗神经退行性疾病和疼痛的化合物
CN109069475B (zh) 2016-04-22 2022-01-28 受体控股公司 快速作用植物类医药化合物和营养补剂
EA201892396A1 (ru) 2016-12-02 2019-04-30 Ресептор Лайф Сайенсиз, Инк. Быстродействующие растительные лекарственные соединения и биологически активные добавки
AU2019385420A1 (en) 2018-11-19 2021-07-08 Spoke Sciences, Inc. N-acylated fatty amino acids to reduce absorption variability in cannabinoid based compositions

Family Cites Families (79)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5518A (en) 1848-04-18 Geaijst-drieb
US4826689A (en) 1984-05-21 1989-05-02 University Of Rochester Method for making uniformly sized particles from water-insoluble organic compounds
FR2634376B1 (fr) 1988-07-21 1992-04-17 Farmalyoc Nouvelle forme unitaire, solide et poreuse comprenant des microparticules et/ou des nanoparticules, ainsi que sa preparation
IT1227626B (it) 1988-11-28 1991-04-23 Vectorpharma Int Farmaci supportati aventi velocita' di dissoluzione aumentata e procedimento per la loro preparazione
US5112820A (en) 1990-03-05 1992-05-12 Sterling Drug Inc. Anti-glaucoma compositions containing 2- and 3-aminomethyl-6-arylcarbonyl- or 6-phenylthio-2,3-dihydropyrrolo-(1,2,3-de)-1,4-benzoxazines and method of use thereof
IT1243390B (it) 1990-11-22 1994-06-10 Vectorpharma Int Composizioni farmaceutiche in forma di particelle atte al rilascio controllato di sostanze farmacologicamente attive e procedimento per la loro preparazione.
US5552160A (en) 1991-01-25 1996-09-03 Nanosystems L.L.C. Surface modified NSAID nanoparticles
US5145684A (en) 1991-01-25 1992-09-08 Sterling Drug Inc. Surface modified drug nanoparticles
HUT63941A (en) * 1992-05-15 1993-11-29 Hoechst Ag Process for producing 4-alkyl-substituted pyrimidine-5-carboxanilide derivatives, and fungicidal compositions comprising same
HUT70952A (en) 1992-06-10 1995-11-28 Eastman Kodak Co Surface modified nanoparticles based on nosteroidal inflammatory drugs, process for preparing them and pharmaceutical compns. contg. them
FR2692575B1 (fr) 1992-06-23 1995-06-30 Sanofi Elf Nouveaux derives du pyrazole, procede pour leur preparation et compositions pharmaceutiques les contenant.
US5346702A (en) 1992-12-04 1994-09-13 Sterling Winthrop Inc. Use of non-ionic cloud point modifiers to minimize nanoparticle aggregation during sterilization
US5298262A (en) 1992-12-04 1994-03-29 Sterling Winthrop Inc. Use of ionic cloud point modifiers to prevent particle aggregation during sterilization
US5302401A (en) 1992-12-09 1994-04-12 Sterling Winthrop Inc. Method to reduce particle size growth during lyophilization
US5340564A (en) 1992-12-10 1994-08-23 Sterling Winthrop Inc. Formulations comprising olin 10-G to prevent particle aggregation and increase stability
US5336507A (en) 1992-12-11 1994-08-09 Sterling Winthrop Inc. Use of charged phospholipids to reduce nanoparticle aggregation
US5429824A (en) 1992-12-15 1995-07-04 Eastman Kodak Company Use of tyloxapole as a nanoparticle stabilizer and dispersant
US5352459A (en) 1992-12-16 1994-10-04 Sterling Winthrop Inc. Use of purified surface modifiers to prevent particle aggregation during sterilization
US5474995A (en) 1993-06-24 1995-12-12 Merck Frosst Canada, Inc. Phenyl heterocycles as cox-2 inhibitors
SK47096A3 (en) * 1993-10-12 1996-10-02 Du Pont Merck Pharma 1n-alkyl-n-arylpyrimidinamines and derivatives thereof
US5466823A (en) 1993-11-30 1995-11-14 G.D. Searle & Co. Substituted pyrazolyl benzenesulfonamides
US5587143A (en) 1994-06-28 1996-12-24 Nanosystems L.L.C. Butylene oxide-ethylene oxide block copolymer surfactants as stabilizer coatings for nanoparticle compositions
US5585108A (en) 1994-12-30 1996-12-17 Nanosystems L.L.C. Formulations of oral gastrointestinal therapeutic agents in combination with pharmaceutically acceptable clays
US5662883A (en) 1995-01-10 1997-09-02 Nanosystems L.L.C. Microprecipitation of micro-nanoparticulate pharmaceutical agents
US5665331A (en) 1995-01-10 1997-09-09 Nanosystems L.L.C. Co-microprecipitation of nanoparticulate pharmaceutical agents with crystal growth modifiers
US5560932A (en) 1995-01-10 1996-10-01 Nano Systems L.L.C. Microprecipitation of nanoparticulate pharmaceutical agents
US5560931A (en) 1995-02-14 1996-10-01 Nawosystems L.L.C. Formulations of compounds as nanoparticulate dispersions in digestible oils or fatty acids
US5571536A (en) 1995-02-06 1996-11-05 Nano Systems L.L.C. Formulations of compounds as nanoparticulate dispersions in digestible oils or fatty acids
US5503723A (en) 1995-02-08 1996-04-02 Eastman Kodak Company Isolation of ultra small particles
US5534270A (en) 1995-02-09 1996-07-09 Nanosystems Llc Method of preparing stable drug nanoparticles
US5518738A (en) 1995-02-09 1996-05-21 Nanosystem L.L.C. Nanoparticulate nsaid compositions
US5622938A (en) 1995-02-09 1997-04-22 Nano Systems L.L.C. Sugar base surfactant for nanocrystals
US5591456A (en) 1995-02-10 1997-01-07 Nanosystems L.L.C. Milled naproxen with hydroxypropyl cellulose as a dispersion stabilizer
EP0809636B1 (en) 1995-02-13 2002-09-04 G.D. Searle & Co. Substituted isoxazoles for the treatment of inflammation
US5633272A (en) 1995-02-13 1997-05-27 Talley; John J. Substituted isoxazoles for the treatment of inflammation
US5573783A (en) 1995-02-13 1996-11-12 Nano Systems L.L.C. Redispersible nanoparticulate film matrices with protective overcoats
US5510118A (en) 1995-02-14 1996-04-23 Nanosystems Llc Process for preparing therapeutic compositions containing nanoparticles
US5580579A (en) 1995-02-15 1996-12-03 Nano Systems L.L.C. Site-specific adhesion within the GI tract using nanoparticles stabilized by high molecular weight, linear poly (ethylene oxide) polymers
US5718919A (en) 1995-02-24 1998-02-17 Nanosystems L.L.C. Nanoparticles containing the R(-)enantiomer of ibuprofen
US5565188A (en) 1995-02-24 1996-10-15 Nanosystems L.L.C. Polyalkylene block copolymers as surface modifiers for nanoparticles
US5747001A (en) 1995-02-24 1998-05-05 Nanosystems, L.L.C. Aerosols containing beclomethazone nanoparticle dispersions
CA2230894A1 (en) * 1995-09-01 1997-03-13 Signal Pharmaceuticals, Inc. Pyrimidine carboxamides and related compounds and methods for treating inflammatory conditions
US5811428A (en) 1995-12-18 1998-09-22 Signal Pharmaceuticals, Inc. Pyrimidine carboxamides and related compounds and methods for treating inflammatory conditions
UA57002C2 (uk) 1995-10-13 2003-06-16 Мерк Фросст Кенада Енд Ко./Мерк Фросст Кенада Енд Сі. Похідне (метилсульфоніл)феніл-2-(5н)-фуранону, фармацевтична композиція та спосіб лікування
ATE386506T1 (de) 1995-10-17 2008-03-15 Jagotec Ag Verabreichung unlöslicher arzneistoffe
FR2742148B1 (fr) * 1995-12-08 1999-10-22 Sanofi Sa Nouveaux derives du pyrazole-3-carboxamide, procede pour leur preparation et compositions pharmaceutiques les contenant
BR9708574A (pt) 1996-04-12 1999-08-03 Searle & Co Derivados benzeno sulfonamida substituídos como pródrogas de inibidores cox-2
NZ333230A (en) 1996-07-18 2000-08-25 Merck Frosst Canada Inc Substituted pyridines as selective cyclooxygenase-2 inhibitors
WO1998035666A1 (en) 1997-02-13 1998-08-20 Nanosystems Llc Formulations of nanoparticle naproxen tablets
CO4960662A1 (es) 1997-08-28 2000-09-25 Novartis Ag Ciertos acidos 5-alquil-2-arilaminofenilaceticos y sus derivados
ES2203985T3 (es) 1997-09-05 2004-04-16 Glaxo Group Limited Derivados de 2,3-diaril-pirazolo(1,5)piridazina, su preparacion y su uso como inhibidores de la ciclooxigenasa 2(cox-2)`.
US6022884A (en) * 1997-11-07 2000-02-08 Amgen Inc. Substituted pyridine compounds and methods of use
CN1160059C (zh) 1998-06-19 2004-08-04 斯凯伊药品加拿大公司 生产水不溶性化合物的亚微粒子的方法
EP1117384A1 (en) 1998-10-01 2001-07-25 Elan Pharma International Limited Controlled release nanoparticulate compositions
ATE275148T1 (de) 1998-11-03 2004-09-15 Glaxo Group Ltd Pyrazolopyridin derivative als selektive cox-2 inhibitoren
US6180136B1 (en) 1998-11-10 2001-01-30 Idexx Laboratories, Inc. Phospholipid-coated microcrystals for the sustained release of pharmacologically active compounds and methods of their manufacture and use
CN1213733C (zh) 1998-11-20 2005-08-10 斯凯伊药品加拿大公司 制备稳定的不溶性微粒的悬浮液的方法
US6025683A (en) 1998-12-23 2000-02-15 Stryker Corporation Motor control circuit for regulating a D.C. motor
GB9828511D0 (en) 1998-12-24 1999-02-17 Zeneca Ltd Chemical compounds
WO2000052008A1 (en) 1999-02-27 2000-09-08 Glaxo Group Limited Pyrazolopyridines
GB9927844D0 (en) * 1999-11-26 2000-01-26 Glaxo Group Ltd Chemical compounds
JP2003523954A (ja) 1999-12-08 2003-08-12 ファルマシア コーポレイション 治療効果が迅速に開始されるシクロオキシゲナーゼ−２阻害剤組成物
GB0003224D0 (en) 2000-02-11 2000-04-05 Glaxo Group Ltd Chemical compounds
SI1294358T1 (en) 2000-06-28 2004-12-31 Smithkline Beecham Plc Wet milling process
GB0016877D0 (en) 2000-07-11 2000-08-30 Astrazeneca Ab Chemical compounds
BR0113628A (pt) 2000-08-31 2003-07-01 Hoffmann La Roche 7-oxo-piridopirimidinas como inibidores de uma proliferação celular
GB0021494D0 (en) 2000-09-01 2000-10-18 Glaxo Group Ltd Chemical comkpounds
CA2436133A1 (en) 2001-01-29 2002-08-08 University Of Connecticut Receptor selective cannabimimetic aminoalkylindoles
US7507767B2 (en) 2001-02-08 2009-03-24 Schering Corporation Cannabinoid receptor ligands
EP1361879A1 (en) 2001-02-20 2003-11-19 Bristol-Myers Squibb Company 2,4-disubstituted pyrimidine-5-carboxamide derivatives as kcnq potassium channel modulators
FR2839718B1 (fr) 2002-05-17 2004-06-25 Sanofi Synthelabo Derives d'indole, leur procede de preparation et les compositions pharmaceutiques en contenant
PE20040574A1 (es) 2002-06-19 2004-09-08 Schering Corp Agonistas de los receptores cannabinoides
ATE530530T1 (de) 2002-06-28 2011-11-15 Astellas Pharma Inc Diaminopyrimidincarbonsäureamidderivat
UY27939A1 (es) * 2002-08-21 2004-03-31 Glaxo Group Ltd Compuestos
WO2004018434A1 (en) 2002-08-21 2004-03-04 Glaxo Group Limited Pyrimidine compounds
GB0222493D0 (en) 2002-09-27 2002-11-06 Glaxo Group Ltd Compounds
JP2006510597A (ja) 2002-09-27 2006-03-30 メルク　エンド　カムパニー　インコーポレーテッド 置換ピリミジン類
GB0222495D0 (en) 2002-09-27 2002-11-06 Glaxo Group Ltd Compounds
TW200505902A (en) 2003-03-20 2005-02-16 Schering Corp Cannabinoid receptor ligands

Also Published As

Publication number Publication date
ECSP055613A (es) 2005-04-18
PE20040898A1 (es) 2005-01-07
BR0313676A (pt) 2005-06-21
OA12910A (en) 2006-10-13
PL376047A1 (en) 2005-12-12
CY1107871T1 (el) 2013-06-19
ATE489369T1 (de) 2010-12-15
CA2495880C (en) 2010-04-27
HK1079193A1 (en) 2006-03-31
ATE377591T1 (de) 2007-11-15
DK1539712T3 (da) 2008-03-17
JP2006501228A (ja) 2006-01-12
NO20051451D0 (no) 2005-03-18
PT1539712E (pt) 2008-02-08
JP4583174B2 (ja) 2010-11-17
KR20050058367A (ko) 2005-06-16
CN1688552A (zh) 2005-10-26
NZ537886A (en) 2007-05-31
US20060293354A1 (en) 2006-12-28
AP2005003219A0 (en) 2005-03-31
MY137053A (en) 2008-12-31
EP1878725B1 (en) 2010-11-24
SI1539712T1 (sl) 2008-04-30
IL166552A0 (en) 2006-01-15
AU2003264076A1 (en) 2004-03-11
AR041016A1 (es) 2005-04-27
EA200500392A1 (ru) 2005-08-25
TW200410946A (en) 2004-07-01
EP1878725A2 (en) 2008-01-16
EA200700934A1 (ru) 2007-08-31
EP1539712A1 (en) 2005-06-15
EP1539712B1 (en) 2007-11-07
CN100351239C (zh) 2007-11-28
IL185549A0 (en) 2008-01-06
AU2003264076B2 (en) 2007-09-20
US7635701B2 (en) 2009-12-22
EA010130B1 (ru) 2008-06-30
MA27428A1 (fr) 2005-07-01
EP1878725A3 (en) 2008-01-30
DE60335151D1 (de) 2011-01-05
CA2495880A1 (en) 2004-03-04
ZA200500913B (en) 2006-07-26
MXPA05001960A (es) 2005-04-28
US20100041654A1 (en) 2010-02-18
DE60317348T2 (de) 2008-08-28
WO2004018433A1 (en) 2004-03-04
UA83194C2 (ru) 2008-06-25
EA012703B1 (ru) 2009-12-30
DE60317348D1 (de) 2007-12-20
UY27939A1 (es) 2004-03-31
ES2295682T3 (es) 2008-04-16
NO20051451L (no) 2005-03-18

Similar Documents

Publication Publication Date Title
IS7749A (is) Pýrimídínafleiður og notkun þeirra sem CB2 beina
IS7881A (is) CHK-, PDK- og AKT-hindrandi pýrimidín, framleiðsla þeirra og notkun sem lyfjaefni
IS7520A (is) Pyrimidínonefnasambönd, samsetningar og aðferðir
DE60333166D1 (de) Pyridin- und pyrimidin-derivate
IS2529B (is) Nýjar spírótrísýklískar afleiður og notkun þeirra sem fosfódíesterasa-7-hindrar
DK1483247T3 (da) Arylsubstituerede pyrimidiner og anvendelsen deraf
DK1572670T3 (da) 5-substitueret-pyrazin eller -pyridin-glucokinaseaktivatorer
ATE478870T1 (de) Spiroindolinpiperidinderivate
ATE460418T1 (de) Heterocyclocarboxamidderivate
DK1551802T3 (da) Indol-3-svovlderivater
ATE467631T1 (de) Chinuclidinamidderivate
ATE438644T1 (de) Chinazolinderivate
ATE438628T1 (de) Pyridazinderivate
IS7720A (is) Píperidín-N-oxíð-afleiður
DK1474408T3 (da) N-Phenyl-2-pyrimidinaminderivater
DK1487805T3 (da) Pyrimidinderivater
IS7717A (is) Pýrídasínónafleiður sem PDF4-hemlar
IL163868A0 (en) Hermiasterlin derivatives and uses thereof
AU2003202091A8 (en) Guanidine derivatives
DE60307512D1 (de) 3h-chinazoline -4-on derivaten
ATE423771T1 (de) Tetrahydrochinolinderivate
DE60323721D1 (de) Verdeckter Reissverschluss
FI20022005A7 (fi) Liitoskappale
PL376897A1 (pl) Podstawione 6-(2-chlorowcofenylo) triazolopirymidyny
DE50306277D1 (de) 4-alkyl-/4-alkenyl-/4-alkinylmethyl/-1-arylcyclohexylamin-derivate